BCR ABL1 Mutation Analysis Test

BCR ABL1 Mutation Analysis detects genetic mutations in the BCR ABL1 fusion gene, specifically for CML.

• To identify genetic mutations in the BCR ABL1 gene for patients with CML • To guide treatment decisions by determining therapy resistance markers • To monitor treatment effectiveness and assess the need for changes in therapy • To provide valuable information for personalized treatment plans

BCR ABL1 Mutation Analysis is recommended for • patients diagnosed with CML, • patients with suspected therapy resistance or treatment failure, • patients whose treatment response needs to be monitored, and • patients requiring personalised treatment plans based on genetic information.

The presence of BCR ABL1 gene mutations may indicate therapy resistance in CML. Abnormal results help doctors identify appropriate treatment options.

During this test, a sample of 5–10 ml of EDTA whole blood will be collected. The sample is sent for analysis using Sanger Sequencing.

• Clinical diagnosis, test prescription, and TRF are mandatory. • Follow any instructions provided by your doctor regarding medication or dietary restrictions. • Inform your doctor if you have any specific requirements.

• Complete Blood Count (CBC): To assess the overall blood cell counts and morphology • BCR ABL1 Quantitative PCR: To monitor treatment response and measure disease burden • Bone Marrow Aspiration and Biopsy: To evaluate the extent of bone marrow involvement

Genetic Testing for Therapy Resistance in Chronic Myeloid Leukaemia

Chronic myeloid leukaemia is a type of cancer that affects the white blood cells. It is characterised by the overproduction of abnormal white blood cells in the bone marrow. CML is often associated with a genetic abnormality known as the Philadelphia chromosome.